Table 2 PI3K pathway inhibitors in clinical development for NHL treatment
From: Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma
Drugs | Target | Clinical trial phase | NHL type | NCT no. |
|---|---|---|---|---|
Pan-isoform PI3K inhibitor | ||||
NVP-BKM120 | Class I PI3K | II (recruiting) | Relapsed and refractory NHL (DLBCL, MCL or FL) | NCT01693614 |
GDC-0941 | Class I PI3K | I (completed) | NHL | NCT00876122 |
BAY80-6946 | Class I PI3K | II (recruiting) | Relapsed, indolent or aggressive NHL (FL, MALT lymphoma, CLL, LPL/WM, DLBCL, MCL, peripheral T-cell lymphoma, ALCL) | NCT01660451 |
Isoform specific PI3K inhibitor | ||||
CAL-101 (GS-1101) | p110δ | III (recruiting) | Previously treated indolent NHL (FL, SLL, LPL/WM, MZL) | NCT01732913 |
I/II (recruiting) | Previously treated low-grade (indolent) B-cell NHL (FL, SLL, MZL) | NCT01306643 | ||
IPI-145 | p110γ/δ | II (recruiting) | Refractory indolent NHL (FL, MZL, or SLL) | NCT01882803 |
I (recruiting) | Relapsed/refractory hematologic malignancies (NHL, CLL, T-cell lymphoma) | NCT01871675 | ||
Dual PI3K/mTOR inhibitor | ||||
NVP-BEZ235 | PI3K/mTOR | I (recruiting) | relapsed or refractory acute leukemia (ALL, AML, CML-BP) | NCT01756118 |
Allosteric mTOR inhibitor | ||||
RAD001 | mTOR | I/II (recruiting) | NHL | NCT01567475 |
I/II (recruiting) | relapsed or refractory NHL or HL | NCT01075321 | ||
| Â | Â | II (completed) | Relapsed or Refractory DLBCL | NCT00869999 |